Main Content start here
Main Layout
Report Description

Report Description

Forecast Period

2027-2031

Market Size (2025)

USD 2.27 Billion

CAGR (2026-2031)

5.56%

Fastest Growing Segment

Oral

Largest Market

Middle East & Africa

Market Size (2031)

USD 3.14 Billion

Market Overview

The Global Tuberculosis Therapeutics Market will grow from USD 2.27 Billion in 2025 to USD 3.14 Billion by 2031 at a 5.56% CAGR. The Global Tuberculosis Therapeutics Market is defined by the commercialization and distribution of pharmacological agents, including first-line and second-line antibiotics, intended to treat active and latent infections caused by Mycobacterium tuberculosis. The market is primarily propelled by the persistent global burden of multi-drug resistant strains and sustained financial commitments from international health organizations aimed at disease eradication. These drivers are fundamental to the sector's baseline demand, distinct from transient technological trends, and ensure steady procurement volume in high-burden regions where government-led procurement models dominate.

However, market expansion is significantly impeded by the chronic underfunding of research and deployment programs, which restricts the development and accessibility of novel regimens for resistant strains. According to the Stop TB Partnership, in late 2024, global funding for tuberculosis research and development reached only US$ 1.2 billion, significantly trailing the annual targets required to effectively curb the epidemic. This financial deficit limits the pipeline of innovative therapeutics and restricts the broader market growth potential in developing economies where the disease burden is highest.

Key Market Drivers

Rising Prevalence of Multi-Drug Resistant Tuberculosis (MDR-TB) serves as a primary market accelerator by intensifying the global necessity for advanced second-line pharmacotherapies and combinatorial treatments. As resistance to standard first-line antibiotics like rifampicin expands, national health programs are compelled to procure specialized, higher-value regimens to contain the epidemic and prevent transmission. According to the World Health Organization, October 2024, in the 'Global Tuberculosis Report 2024', an estimated 400,000 people developed multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) in 2023, creating a critical and sustained demand for robust pharmaceutical interventions. This epidemiological burden directly influences market dynamics by shifting procurement priorities toward novel chemical entities and auxiliary drugs capable of addressing these complex resistance profiles, thereby driving value growth within the anti-infective therapeutic segment.

Simultaneously, the Introduction of Shorter and More Effective Treatment Regimens is fundamentally reshaping clinical protocols and increasing the adoption of innovative oral therapies. The transition from lengthy, injectable-based courses to streamlined all-oral regimens, such as BPaL (bedaquiline, pretomanid, and linezolid), significantly improves patient adherence and clinical success rates, encouraging rapid uptake by healthcare authorities. According to the World Health Organization, October 2024, in the 'Global Tuberculosis Report 2024', the global treatment success rate for MDR/RR-TB rose to 68%, a major improvement largely attributed to the implementation of these modernized, less toxic therapeutic protocols. Supporting this scale of deployment, the Global Fund, September 2024, in the 'Results Report 2024', reported that health programs supported by its partnership treated a record 7.1 million people for tuberculosis in 2023, underscoring the massive volume of therapeutics required to support these evolved public health strategies.

Download Free Sample Report

Key Market Challenges

Chronic underfunding serves as a substantial barrier to the commercial progress of the tuberculosis therapeutics sector. When capital is insufficient, it directly restricts the operational capacity of national health programs to purchase and distribute necessary antibiotic regimens. This financial limitation disrupts the supply chain, preventing manufacturers from scaling production for new drug formulations designed to treat resistant strains. Without consistent funding flows, pharmaceutical companies face reduced incentives to invest in the costly development of novel therapeutics, resulting in a stagnated product pipeline that fails to meet evolving clinical needs.

The impact of this deficit is most pronounced in high-burden regions where dependence on external donor funding is high. A lack of resources prevents the widespread adoption of newer treatment courses, forcing healthcare systems to rely on older medications. According to the World Health Organization, in 2024, only US$ 5.7 billion was available for essential tuberculosis diagnosis, treatment, and prevention services, falling well short of the global requirement. This persistent gap between required resources and actual availability constrains the addressable market size and limits revenue opportunities for therapeutic developers.

Key Market Trends

Innovation in Pediatric-Friendly Dispersible Fixed-Dose Combinations is transforming the pediatric treatment landscape by replacing the inaccurate practice of splitting adult tablets with precise, palatable formulations. These water-dispersible tablets improve adherence and bioavailability in young patients, a demographic historically neglected in drug development. This shift is being prioritized by global health bodies to close the diagnosis-treatment gap, forcing a market evolution away from makeshift dosing strategies toward standardized pediatric products. According to the World Health Organization, November 2024, in the 'Inclusion for every child' update, a record 700,000 children were notified with tuberculosis in 2023, a surge that is directly compelling manufacturers and procurement agencies to scale the production and distribution of these specialized, age-appropriate therapeutic courses to meet the expanding verified demand.

Integration of Artificial Intelligence in Anti-Tubercular Drug Discovery is fundamentally altering the R&D pipeline by deploying generative models to identify novel chemical entities and drug targets. Pharmaceutical developers are leveraging machine learning algorithms to screen vast molecular libraries and predict pharmacological interactions, thereby reducing the time and capital required for hit-to-lead optimization. This technological adoption is critical for populating the pipeline with new classes of antibiotics capable of circumventing existing resistance mechanisms efficiently. According to Microsoft Research, November 2024, in the 'Accelerating drug discovery with TamGen' report, a joint initiative with the Global Health Drug Discovery Institute successfully utilized a generative AI chemical language model to synthesize and identify promising proteolysis-targeting inhibitors from a pool of 2,600 generated compounds, demonstrating the efficiency of computational methods in accelerating early-stage discovery.

Segmental Insights

The Oral administration segment is projected to register the fastest growth in the Global Tuberculosis Therapeutics Market due to a fundamental shift in treatment protocols recommended by the World Health Organization. This transition emphasizes the replacement of traditional injectable agents with all-oral regimens for treating drug-resistant tuberculosis to enhance patient compliance and mitigate adverse effects. The global adoption of these simplified therapies minimizes the logistical burdens often associated with long-term hospitalization and complex administration. Consequently, the rising clinical preference for non-invasive treatment options continues to accelerate the development and commercialization of oral therapeutic solutions worldwide.

Regional Insights

The Middle East and Africa region currently holds the leading position in the Global Tuberculosis Therapeutics Market, driven primarily by the high prevalence of active tuberculosis cases across the continent. This dominance is sustained by the substantial disease burden, particularly in Sub-Saharan Africa, where HIV-TB co-infection rates remain significant, necessitating extensive therapeutic intervention. Furthermore, robust support from international bodies, such as the World Health Organization and the Global Fund, facilitates large-scale procurement and distribution of essential anti-tubercular drugs. Governments in key nations like South Africa are also prioritizing public health mandates to scale up access to treatment, thereby securing the region’s commanding market share.

Recent Developments

  • In September 2025, Lupin Limited announced that it had been granted prequalification by the World Health Organization (WHO) for its pretomanid product, a key drug used in the treatment of drug-resistant tuberculosis. This certification provided assurance regarding the safety, quality, and efficacy of the company's 200 mg tablet formulation, allowing it to be procured by international agencies such as the Global Fund. The approval positioned the company to expand global access to this critical therapy, which is a cornerstone of the six-month all-oral BPaL (bedaquiline, pretomanid, and linezolid) regimen.
  • In July 2024, Johnson & Johnson received traditional approval from the U.S. Food and Drug Administration (FDA) for SIRTURO (bedaquiline) as part of a combination therapy for adult and pediatric patients aged 5 years and older with pulmonary tuberculosis. This regulatory milestone removed the restrictions previously associated with the drug's accelerated approval status granted in 2012. The decision was supported by data from a large-scale Phase 3 study, which confirmed that the bedaquiline-containing regimen offered significant improvements in treatment outcomes compared to injectable-containing regimens for drug-resistant forms of the infection.
  • In May 2024, BioVersys expanded its strategic collaboration with GSK to accelerate the clinical development of alpibectir (BVL-GSK098), a novel small molecule for the treatment of tuberculosis. As part of the agreement, GSK committed to an equity investment in BioVersys, extending the company’s Series C financing round by CHF 12.3 million. The partners aimed to develop the drug candidate for both pulmonary and bio-meningitis tuberculosis programs, leveraging a unique mechanism of action designed to overcome resistance and potentiate the activity of existing antibiotics like ethionamide.
  • In March 2024, Otsuka Pharmaceutical announced positive interim data from a Phase 2b/c clinical trial evaluating the investigational compound quabodepistat in combination with delamanid and bedaquiline for the treatment of pulmonary tuberculosis. The results, presented at a major medical conference, indicated that the four-month regimen containing quabodepistat achieved safety and efficacy outcomes comparable to the standard six-month standard-of-care regimen in participants with drug-susceptible tuberculosis. This development highlighted the potential of the new compound to shorten treatment duration and improve patient adherence in the fight against the disease.

Key Market Players

  • AstraZeneca PLC
  • Johnson & Johnson Services, Inc.
  • Eli Lilly and Company
  • Mylan Inc.
  • Teva Pharmaceutical Industries Ltd
  • Sanofi S.A.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Pfizer Inc.

By Disease Type

By Therapy

By Route of Administration

By Dosage Form

By Distribution Channel

By Region

  • Active TB
  • Latent TB
  • First-Line Therapy
  • Second-Line Therapy
  • Oral
  • Parenteral
  • Others
  • Tablets
  • Capsules
  • Injection
  • Others
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

Report Scope:

In this report, the Global Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Tuberculosis Therapeutics Market, By Disease Type:
  • Active TB
  • Latent TB
  • Tuberculosis Therapeutics Market, By Therapy:
  • First-Line Therapy
  • Second-Line Therapy
  • Tuberculosis Therapeutics Market, By Route of Administration:
  • Oral
  • Parenteral
  • Others
  • Tuberculosis Therapeutics Market, By Dosage Form:
  • Tablets
  • Capsules
  • Injection
  • Others
  • Tuberculosis Therapeutics Market, By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Tuberculosis Therapeutics Market, By Region:
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tuberculosis Therapeutics Market.

Available Customizations:

Global Tuberculosis Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Tuberculosis Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.  Markets Covered

1.2.2.  Years Considered for Study

1.2.3.  Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Tuberculosis Therapeutics Market Outlook

5.1.  Market Size & Forecast

5.1.1.  By Value

5.2.  Market Share & Forecast

5.2.1.  By Disease Type (Active TB, Latent TB)

5.2.2.  By Therapy (First-Line Therapy, Second-Line Therapy)

5.2.3.  By Route of Administration (Oral, Parenteral, Others)

5.2.4.  By Dosage Form (Tablets, Capsules, Injection, Others)

5.2.5.  By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

5.2.6.  By Region

5.2.7.  By Company (2025)

5.3.  Market Map

6.    North America Tuberculosis Therapeutics Market Outlook

6.1.  Market Size & Forecast

6.1.1.  By Value

6.2.  Market Share & Forecast

6.2.1.  By Disease Type

6.2.2.  By Therapy

6.2.3.  By Route of Administration

6.2.4.  By Dosage Form

6.2.5.  By Distribution Channel

6.2.6.  By Country

6.3.    North America: Country Analysis

6.3.1.    United States Tuberculosis Therapeutics Market Outlook

6.3.1.1.  Market Size & Forecast

6.3.1.1.1.  By Value

6.3.1.2.  Market Share & Forecast

6.3.1.2.1.  By Disease Type

6.3.1.2.2.  By Therapy

6.3.1.2.3.  By Route of Administration

6.3.1.2.4.  By Dosage Form

6.3.1.2.5.  By Distribution Channel

6.3.2.    Canada Tuberculosis Therapeutics Market Outlook

6.3.2.1.  Market Size & Forecast

6.3.2.1.1.  By Value

6.3.2.2.  Market Share & Forecast

6.3.2.2.1.  By Disease Type

6.3.2.2.2.  By Therapy

6.3.2.2.3.  By Route of Administration

6.3.2.2.4.  By Dosage Form

6.3.2.2.5.  By Distribution Channel

6.3.3.    Mexico Tuberculosis Therapeutics Market Outlook

6.3.3.1.  Market Size & Forecast

6.3.3.1.1.  By Value

6.3.3.2.  Market Share & Forecast

6.3.3.2.1.  By Disease Type

6.3.3.2.2.  By Therapy

6.3.3.2.3.  By Route of Administration

6.3.3.2.4.  By Dosage Form

6.3.3.2.5.  By Distribution Channel

7.    Europe Tuberculosis Therapeutics Market Outlook

7.1.  Market Size & Forecast

7.1.1.  By Value

7.2.  Market Share & Forecast

7.2.1.  By Disease Type

7.2.2.  By Therapy

7.2.3.  By Route of Administration

7.2.4.  By Dosage Form

7.2.5.  By Distribution Channel

7.2.6.  By Country

7.3.    Europe: Country Analysis

7.3.1.    Germany Tuberculosis Therapeutics Market Outlook

7.3.1.1.  Market Size & Forecast

7.3.1.1.1.  By Value

7.3.1.2.  Market Share & Forecast

7.3.1.2.1.  By Disease Type

7.3.1.2.2.  By Therapy

7.3.1.2.3.  By Route of Administration

7.3.1.2.4.  By Dosage Form

7.3.1.2.5.  By Distribution Channel

7.3.2.    France Tuberculosis Therapeutics Market Outlook

7.3.2.1.  Market Size & Forecast

7.3.2.1.1.  By Value

7.3.2.2.  Market Share & Forecast

7.3.2.2.1.  By Disease Type

7.3.2.2.2.  By Therapy

7.3.2.2.3.  By Route of Administration

7.3.2.2.4.  By Dosage Form

7.3.2.2.5.  By Distribution Channel

7.3.3.    United Kingdom Tuberculosis Therapeutics Market Outlook

7.3.3.1.  Market Size & Forecast

7.3.3.1.1.  By Value

7.3.3.2.  Market Share & Forecast

7.3.3.2.1.  By Disease Type

7.3.3.2.2.  By Therapy

7.3.3.2.3.  By Route of Administration

7.3.3.2.4.  By Dosage Form

7.3.3.2.5.  By Distribution Channel

7.3.4.    Italy Tuberculosis Therapeutics Market Outlook

7.3.4.1.  Market Size & Forecast

7.3.4.1.1.  By Value

7.3.4.2.  Market Share & Forecast

7.3.4.2.1.  By Disease Type

7.3.4.2.2.  By Therapy

7.3.4.2.3.  By Route of Administration

7.3.4.2.4.  By Dosage Form

7.3.4.2.5.  By Distribution Channel

7.3.5.    Spain Tuberculosis Therapeutics Market Outlook

7.3.5.1.  Market Size & Forecast

7.3.5.1.1.  By Value

7.3.5.2.  Market Share & Forecast

7.3.5.2.1.  By Disease Type

7.3.5.2.2.  By Therapy

7.3.5.2.3.  By Route of Administration

7.3.5.2.4.  By Dosage Form

7.3.5.2.5.  By Distribution Channel

8.    Asia Pacific Tuberculosis Therapeutics Market Outlook

8.1.  Market Size & Forecast

8.1.1.  By Value

8.2.  Market Share & Forecast

8.2.1.  By Disease Type

8.2.2.  By Therapy

8.2.3.  By Route of Administration

8.2.4.  By Dosage Form

8.2.5.  By Distribution Channel

8.2.6.  By Country

8.3.    Asia Pacific: Country Analysis

8.3.1.    China Tuberculosis Therapeutics Market Outlook

8.3.1.1.  Market Size & Forecast

8.3.1.1.1.  By Value

8.3.1.2.  Market Share & Forecast

8.3.1.2.1.  By Disease Type

8.3.1.2.2.  By Therapy

8.3.1.2.3.  By Route of Administration

8.3.1.2.4.  By Dosage Form

8.3.1.2.5.  By Distribution Channel

8.3.2.    India Tuberculosis Therapeutics Market Outlook

8.3.2.1.  Market Size & Forecast

8.3.2.1.1.  By Value

8.3.2.2.  Market Share & Forecast

8.3.2.2.1.  By Disease Type

8.3.2.2.2.  By Therapy

8.3.2.2.3.  By Route of Administration

8.3.2.2.4.  By Dosage Form

8.3.2.2.5.  By Distribution Channel

8.3.3.    Japan Tuberculosis Therapeutics Market Outlook

8.3.3.1.  Market Size & Forecast

8.3.3.1.1.  By Value

8.3.3.2.  Market Share & Forecast

8.3.3.2.1.  By Disease Type

8.3.3.2.2.  By Therapy

8.3.3.2.3.  By Route of Administration

8.3.3.2.4.  By Dosage Form

8.3.3.2.5.  By Distribution Channel

8.3.4.    South Korea Tuberculosis Therapeutics Market Outlook

8.3.4.1.  Market Size & Forecast

8.3.4.1.1.  By Value

8.3.4.2.  Market Share & Forecast

8.3.4.2.1.  By Disease Type

8.3.4.2.2.  By Therapy

8.3.4.2.3.  By Route of Administration

8.3.4.2.4.  By Dosage Form

8.3.4.2.5.  By Distribution Channel

8.3.5.    Australia Tuberculosis Therapeutics Market Outlook

8.3.5.1.  Market Size & Forecast

8.3.5.1.1.  By Value

8.3.5.2.  Market Share & Forecast

8.3.5.2.1.  By Disease Type

8.3.5.2.2.  By Therapy

8.3.5.2.3.  By Route of Administration

8.3.5.2.4.  By Dosage Form

8.3.5.2.5.  By Distribution Channel

9.    Middle East & Africa Tuberculosis Therapeutics Market Outlook

9.1.  Market Size & Forecast

9.1.1.  By Value

9.2.  Market Share & Forecast

9.2.1.  By Disease Type

9.2.2.  By Therapy

9.2.3.  By Route of Administration

9.2.4.  By Dosage Form

9.2.5.  By Distribution Channel

9.2.6.  By Country

9.3.    Middle East & Africa: Country Analysis

9.3.1.    Saudi Arabia Tuberculosis Therapeutics Market Outlook

9.3.1.1.  Market Size & Forecast

9.3.1.1.1.  By Value

9.3.1.2.  Market Share & Forecast

9.3.1.2.1.  By Disease Type

9.3.1.2.2.  By Therapy

9.3.1.2.3.  By Route of Administration

9.3.1.2.4.  By Dosage Form

9.3.1.2.5.  By Distribution Channel

9.3.2.    UAE Tuberculosis Therapeutics Market Outlook

9.3.2.1.  Market Size & Forecast

9.3.2.1.1.  By Value

9.3.2.2.  Market Share & Forecast

9.3.2.2.1.  By Disease Type

9.3.2.2.2.  By Therapy

9.3.2.2.3.  By Route of Administration

9.3.2.2.4.  By Dosage Form

9.3.2.2.5.  By Distribution Channel

9.3.3.    South Africa Tuberculosis Therapeutics Market Outlook

9.3.3.1.  Market Size & Forecast

9.3.3.1.1.  By Value

9.3.3.2.  Market Share & Forecast

9.3.3.2.1.  By Disease Type

9.3.3.2.2.  By Therapy

9.3.3.2.3.  By Route of Administration

9.3.3.2.4.  By Dosage Form

9.3.3.2.5.  By Distribution Channel

10.    South America Tuberculosis Therapeutics Market Outlook

10.1.  Market Size & Forecast

10.1.1.  By Value

10.2.  Market Share & Forecast

10.2.1.  By Disease Type

10.2.2.  By Therapy

10.2.3.  By Route of Administration

10.2.4.  By Dosage Form

10.2.5.  By Distribution Channel

10.2.6.  By Country

10.3.    South America: Country Analysis

10.3.1.    Brazil Tuberculosis Therapeutics Market Outlook

10.3.1.1.  Market Size & Forecast

10.3.1.1.1.  By Value

10.3.1.2.  Market Share & Forecast

10.3.1.2.1.  By Disease Type

10.3.1.2.2.  By Therapy

10.3.1.2.3.  By Route of Administration

10.3.1.2.4.  By Dosage Form

10.3.1.2.5.  By Distribution Channel

10.3.2.    Colombia Tuberculosis Therapeutics Market Outlook

10.3.2.1.  Market Size & Forecast

10.3.2.1.1.  By Value

10.3.2.2.  Market Share & Forecast

10.3.2.2.1.  By Disease Type

10.3.2.2.2.  By Therapy

10.3.2.2.3.  By Route of Administration

10.3.2.2.4.  By Dosage Form

10.3.2.2.5.  By Distribution Channel

10.3.3.    Argentina Tuberculosis Therapeutics Market Outlook

10.3.3.1.  Market Size & Forecast

10.3.3.1.1.  By Value

10.3.3.2.  Market Share & Forecast

10.3.3.2.1.  By Disease Type

10.3.3.2.2.  By Therapy

10.3.3.2.3.  By Route of Administration

10.3.3.2.4.  By Dosage Form

10.3.3.2.5.  By Distribution Channel

11.    Market Dynamics

11.1.  Drivers

11.2.  Challenges

12.    Market Trends & Developments

12.1.  Merger & Acquisition (If Any)

12.2.  Product Launches (If Any)

12.3.  Recent Developments

13.    Global Tuberculosis Therapeutics Market: SWOT Analysis

14.    Porter's Five Forces Analysis

14.1.  Competition in the Industry

14.2.  Potential of New Entrants

14.3.  Power of Suppliers

14.4.  Power of Customers

14.5.  Threat of Substitute Products

15.    Competitive Landscape

15.1.  AstraZeneca PLC

15.1.1.  Business Overview

15.1.2.  Products & Services

15.1.3.  Recent Developments

15.1.4.  Key Personnel

15.1.5.  SWOT Analysis

15.2.  Johnson & Johnson Services, Inc.

15.3.  Eli Lilly and Company

15.4.  Mylan Inc.

15.5.  Teva Pharmaceutical Industries Ltd

15.6.  Sanofi S.A.

15.7.  Novartis AG

15.8.  Sun Pharmaceutical Industries Ltd

15.9.  Pfizer Inc.

16.    Strategic Recommendations

17.    About Us & Disclaimer

Figures and Tables

Frequently asked questions

Frequently asked questions

The market size of the Global Tuberculosis Therapeutics Market was estimated to be USD 2.27 Billion in 2025.

Middle East & Africa is the dominating region in the Global Tuberculosis Therapeutics Market.

Oral segment is the fastest growing segment in the Global Tuberculosis Therapeutics Market.

The Global Tuberculosis Therapeutics Market is expected to grow at 5.56% between 2026 to 2031.

Related Reports

We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site or by closing this box, you consent to our use of cookies. More info.